ND-022

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameND-022

Drug Alias NameND-022

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-HER2Anti-CD3 +[4]

TargetsReceptor protein-tyrosine kinase erbB-2Programmed death-ligand 1T cell surface glycoprotein CD3 +[4]

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNumab Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesNumab Therapeutics Ag

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A